{"id":"gabapentin-immediate-release","safety":{"commonSideEffects":[{"rate":"17-28","effect":"Dizziness"},{"rate":"21-27","effect":"Somnolence"},{"rate":"13-15","effect":"Ataxia"},{"rate":"6-11","effect":"Fatigue"},{"rate":"5-8","effect":"Peripheral edema"},{"rate":"6-9","effect":"Tremor"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By binding to presynaptic calcium channels, gabapentin decreases calcium influx and subsequently reduces the release of glutamate and other excitatory neurotransmitters. This leads to reduced neuronal excitability and is thought to underlie its analgesic and anticonvulsant effects. The exact mechanism in pain conditions remains incompletely understood but involves modulation of neuropathic pain pathways.","oneSentence":"Gabapentin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:40:01.043Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Postherpetic neuralgia"},{"name":"Partial-onset seizures (adjunctive therapy)"},{"name":"Neuropathic pain"}]},"trialDetails":[{"nctId":"NCT06097676","phase":"PHASE4","title":"An Abuse Potential Study of Orally Administered HORIZANT in Healthy, Non-dependent, Recreational Drug Users","status":"COMPLETED","sponsor":"Arbor Pharmaceuticals, Inc.","startDate":"2021-09-28","conditions":"Abuse Potential","enrollment":86},{"nctId":"NCT05252858","phase":"NA","title":"A Pilot Study Investigating the nCAP Signal Relief Patch in Subjects Undergoing Primary Hip or Knee Replacement Surgery","status":"COMPLETED","sponsor":"Jacques E. Chelly","startDate":"2022-03-21","conditions":"Opioid Use, Pain, Post Operative","enrollment":79},{"nctId":"NCT03708237","phase":"PHASE2","title":"Effectiveness of Ropinirole and Gabapentin for the Treatment of RLS in Patients on Maintenance HD","status":"TERMINATED","sponsor":"University of Alberta","startDate":"2019-02-19","conditions":"Restless Legs Syndrome, End Stage Renal Disease","enrollment":3},{"nctId":"NCT02117076","phase":"PHASE4","title":"Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome","status":"TERMINATED","sponsor":"Theresa Zesiewicz, MD","startDate":"2014-04","conditions":"Restless Leg Syndrome","enrollment":5},{"nctId":"NCT03334903","phase":"PHASE4","title":"Gabapentin Regimens and Their Effects on Opioid Consumption","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2018-05-15","conditions":"Knee Osteoarthritis, Knee Pain Chronic, Opioid Use","enrollment":77},{"nctId":"NCT03275012","phase":"PHASE2","title":"Efficacy and Safety Study of Gabapentin as add-on to Morphine in Paediatric Patients Affected by Chronic Pain","status":"WITHDRAWN","sponsor":"Pharmaceutical Research Management srl","startDate":"2017-04-04","conditions":"Chronic Pain","enrollment":""}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"PRODUCT DISPENSING ERROR"},{"count":1,"reaction":"PRODUCT LABEL CONFUSION"},{"count":1,"reaction":"PRODUCT NAME CONFUSION"}],"_approvalHistory":[],"publicationCount":39,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Neurontin"],"phase":"marketed","status":"active","brandName":"Gabapentin immediate release","genericName":"Gabapentin immediate release","companyName":"Theresa Zesiewicz, MD","companyId":"theresa-zesiewicz-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gabapentin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters. Used for Postherpetic neuralgia, Partial-onset seizures (adjunctive therapy), Neuropathic pain.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}